EURETINA

Prof. Anat Lowenstein of Tel Aviv University, Israel, discusses the innovative moves towards incorporating head-wearable devices in surgical theatres and the importance of improving outcomes in the management of AMD patients with home monitoring, a field particularly noteworthy during the COVID-19 pandemic.

Dr Tunde Peto explains that the rate of blindness from diabetes continues to increase by 8% annually and the only way to prevent this may well rest with well-planned, evidence-based services.

A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.

Mehran Nouroozian, Regional Manager at Oertli for the Middle East Region, India, and Turkey at Oertli, shows off the company’s newest product additions during this year's virtual meeting.

Prof. Frank Holz, Chairman of the Department of Ophthalmology at the University of Bonn, Germany, highlights the topics, lectures, symposia and instructional courses that will take place at this year’s virtual EURETINA conference, and gives his insights on the hot topics of the dynamic retina field.

Heads-up surgery is moving into the next generation of vitreoretinal surgery, with novel technologies being developed for surgeons.

The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa.

Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.